Valneva Shares Drop 3.19% Midday Ahead of Annual Results
Valneva is losing ground this Friday midday, continuing a negative week for the Nantes-based vaccine specialist's stock. The share price stands at 4.548 euros, down 3.19% from the previous day's close. The publication of the 2025 annual results, expected on March 16, is the next major milestone for the company.
Valneva shares are trading at 4.548 euros, showing a decline of 3.03% over the past seven days. However, this movement occurs within the context of a clearly positive medium-term trajectory, with the stock showing an increase of 19.06% over three months and nearly 39.5% over a year. Technically, the price still moves above its 50-day moving average, which is at 4.24 euros, indicating that the bullish trend remains intact at this stage. The RSI, at 59, reflects a balance zone, away from both overbought and oversold thresholds. The next resistance threshold is at 5.08 euros, while the most relevant support is at 3.89 euros, a level significantly lower than the current price.
Financial Calendar and Key Dates
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Valneva's financial calendar schedules the publication of the 2025 annual results for March 16, which is in ten days. This deadline is a crucial moment to assess the commercial and financial trajectory of the laboratory, particularly the evolution of its revenues from vaccines against chikungunya (Ixchiq) and Japanese encephalitis (Ixiaro). Subsequently, the results for the first quarter of 2026 are scheduled for May 7, and the general meeting will take place on June 1. It is worth noting that the stock has a beta of 0.26, indicating a low correlation with overall market movements, which reflects a profile specific to the company's own fundamentals rather than broad macroeconomic trends.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 65,8 millions d'euros
Quarterly revenue: 65,8 millions d'euros
Revenue growth: -32,6 %
EBITDA: -39,8 millions d'euros
Net income: -63,3 millions d'euros
Guidance from the release
Malgré l'impact négatif persistant du contexte géopolitique sur les voyages, Valneva a confirmé ses perspectives pour 2026
Risks mentioned
Impact négatif persistant du contexte géopolitique sur les voyages affectant les ventes de produits
Dépendance commerciale élevée envers les livraisons d'IXIARO au Département américain de la Défense avec calendrier incertain
Recentrage stratégique d'IXCHIQ sur les marchés endémiques affectant les perspectives commerciales du vaccin contre le chikungunya
Opportunities identified
Décisions réglementaires attendues pour le candidat vaccin LB6V contre la maladie de Lyme dans les 12 prochains mois
Amélioration attendue des marges brutes au second semestre après impact d'éléments non récurrents au S1 2026
Bénéfices futurs de l'initiative de restructuration visant à réduire la consommation de trésorerie et optimiser les opérations
Outlook / guidance
Expected revenue: 147,5 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
